Table 1.
Characteristics of the included studies
| Authors, referenes | Country | Type of study | Year of Pub | Study population | N pts | Setting of disease | Comparison with 2-[18F]FDG | Type of tracer (Injected dose) |
|---|---|---|---|---|---|---|---|---|
| Lindner et al. [8] | Germany | P | 2018 | Mixed | 2 | Restaging | No |
[68 Ga]Ga-FAPI-04 (80 nmol/GBq) |
| Kratochwil et al. [9] | Germany | R | 2019 | Mixed | 12 | Not clear | No |
[68 Ga]Ga-FAPI-04 (122–312 MBq) |
| Ballal et al. [11] | India | P | 2020 | Mixed | 19 | Staging and restaging | Yes |
[68 Ga]Ga- DOTA.SA.FAPi (mean: 174 MBq) |
| Chen et al. [10] | China | P | 2020 | Mixed | 4 | Staging and restaging | Yes |
[68 Ga]Ga-FAPI-04 (180–220 MBq) |
| Komek et al. [18] | Turkey | P | 2021 | Breast cancer | 20 | Staging and restaging | Yes |
[68 Ga]Ga-FAPI-04 (2 MBq/Kg) |
| Dendl et al. [12] | Germany | R | 2021 | Mixed | 14 | Not clear | Yes |
[68 Ga]Ga-FAPI-04 (52–325 MBq) |
| Elboga et al. [19] | Turkey | R | 2021 | Breast cancer | 48 | Staging and restaging | Yes |
[68 Ga]Ga-FAPI-04 (2 MBq/Kg) |
| Backhaus et al. [13] | Germany | R | 2022 | Mixed | 8 | Staging and Restaging | No |
[68 Ga]Ga-Onco-FAP (163.3 ± 50 MBq) |
| Backhaus et al. [16] | Germany | R | 2022 | Breast cancer | 19 | Staging and Restaging | No |
[68 Ga]Ga-FAPI-46 (149 ± 48 MBq) |
| Mona et al. [14] | US | P | 2022 | Mixed | 2 | Not clear | No |
[68 Ga]Ga-FAPI-46 (174–185 MBq) |
| Airo’ Farulla LS et al. [15] | Italy | R | 2022 | Mixed | 2 | Restaging | Yes |
[68 Ga]Ga-FAPI-04 (not available) |
| Eshet et al. [20] | Israel | P | 2022 | Breast cancer | 7 | Not clear | No |
[68 Ga]Ga-FAPI-04 (185 MBq) |
| Backhaus et al. [17] | Germany | R | 2022 | Breast cancer | 13 | Restaging (post-NAC) | No |
[68 Ga]Ga-FAPI-46 (99 ± 33 MBq) |
*Comparison [68 Ga]Ga-FAPI-46; NAC neoadjuvant chemotherapy; R = retrospective; P = prospective